Tscan Therapeutics (TCRX) Income Statement (2020 - 2025)
Income Statement report data from Jun 30, 2020 to Sep 30, 2025 for Tscan Therapeutics (TCRX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||||||||||
Total Revenue | 2.51M (-18.51%) | 3.08M (+41.94%) | 2.17M (+223.88%) | 670K (-36.19%) | 1.05M (+94.44%) | 540K (-5.26%) | 570K (-92.09%) | 7.21M (+85.35%) | 3.89M (+23.49%) | 3.15M (-53.68%) | 6.80M (+119.35%) | 3.10M (-7.74%) | 3.36M (-17.24%) | 4.06M (+34.44%) | 3.02M (+5.96%) | 2.85M (+18.26%) | 2.41M (-15.44%) | 2.85M (+40.39%) | 2.03M (+600.00%) | 290K | - |
Operating Expenses | |||||||||||||||||||||
Research And Development | 32M (-2.88%) | 33M (+9.53%) | 30M (+1.50%) | 29M (+11.77%) | 26M (-2.31%) | 27M (+8.13%) | 25M (+10.93%) | 22M (-1.45%) | 23M (+7.11%) | 21M (-2.53%) | 22M (+39.62%) | 16M (+3.79%) | 15M (+3.73%) | 14M (-1.36%) | 15M (+16.49%) | 13M (-11.26%) | 14M (+31.57%) | 11M (+47.14%) | 7.34M (+26.33%) | 5.81M (+29.11%) | 4.50M |
Selling General And Administrative | 7.87M (-13.52%) | 9.10M (+5.45%) | 8.63M (+7.61%) | 8.02M (+8.23%) | 7.41M (-4.63%) | 7.77M (+9.75%) | 7.08M (+14.94%) | 6.16M (+4.58%) | 5.89M (-9.80%) | 6.53M (-15.96%) | 7.77M (+26.55%) | 6.14M (+25.05%) | 4.91M (+2.08%) | 4.81M (+7.13%) | 4.49M (+0.90%) | 4.45M (+9.88%) | 4.05M (+48.35%) | 2.73M (+4.60%) | 2.61M (+58.18%) | 1.65M (+48.65%) | 1.11M |
Operating Expenses | 40M (-5.20%) | 42M (+8.62%) | 38M (+2.78%) | 37M (+11.02%) | 34M (-2.83%) | 35M (+8.48%) | 32M (+11.80%) | 29M (-0.24%) | 29M (+3.17%) | 28M (-6.06%) | 30M (+35.92%) | 22M (+9.03%) | 20M (+3.32%) | 19M (+0.63%) | 19M (+12.43%) | 17M (-6.52%) | 18M (+34.89%) | 14M (+35.98%) | 9.95M (+33.38%) | 7.46M (+32.74%) | 5.62M |
Depreciation And Amortization | - | - | 680K (-76.14%) | 2.85M | - | - | 1.25M (-67.95%) | 3.90M | - | - | 1.50M (-61.64%) | 3.91M | - | - | 1.20M (-57.60%) | 2.83M | - | - | 470K | - | - |
Operating Income | |||||||||||||||||||||
Operating Income | -37.05M (-4.14%) | -38.65M (+6.62%) | -36.25M (-1.25%) | -36.71M (+12.54%) | -32.62M (-4.37%) | -34.11M (+8.73%) | -31.37M (+46.86%) | -21.36M (-13.70%) | -24.75M (+0.57%) | -24.61M (+8.22%) | -22.74M (+21.93%) | -18.65M (+12.48%) | -16.58M (+8.72%) | -15.25M (-5.63%) | -16.16M (+13.80%) | -14.20M (-10.35%) | -15.84M (+48.31%) | -10.68M (+34.85%) | -7.92M (+10.46%) | -7.17M (+27.58%) | -5.62M |
Ebit | -37.05M (-4.14%) | -38.65M (+6.62%) | -36.25M (-1.25%) | -36.71M (+12.54%) | -32.62M (-4.37%) | -34.11M (+8.73%) | -31.37M (+46.86%) | -21.36M (-13.70%) | -24.75M (+0.57%) | -24.61M (+8.22%) | -22.74M (+21.93%) | -18.65M (+12.48%) | -16.58M (+8.72%) | -15.25M (-5.63%) | -16.16M (+13.80%) | -14.20M (-10.35%) | -15.84M (+48.31%) | -10.68M (+34.85%) | -7.92M (+10.46%) | -7.17M (+27.58%) | -5.62M |
EBITDA | -35.01M (-3.45%) | -36.26M (+1.94%) | -35.57M (-13.16%) | -40.96M (+41.58%) | -28.93M (-5.80%) | -30.71M (+1.96%) | -30.12M (+38.67%) | -21.72M (-1.32%) | -22.01M (-4.64%) | -23.08M (+8.66%) | -21.24M (+37.65%) | -15.43M (-3.80%) | -16.04M (+6.23%) | -15.10M (+0.87%) | -14.97M (+31.55%) | -11.38M (-28.16%) | -15.84M (+48.45%) | -10.67M (+43.22%) | -7.45M (+3.91%) | -7.17M (+27.81%) | -5.61M |
Other Income / Expenses | |||||||||||||||||||||
Interest Expense | 700K (+1.45%) | 690K (+1.47%) | 680K (-12.82%) | 780K (-18.75%) | 960K (+1.05%) | 950K (-1.04%) | 960K (+12.94%) | 850K (-13.27%) | 980K (+1.03%) | 970K (+1.04%) | 960K (-2.04%) | 980K (+390.00%) | 200K | - | - | - | - | - | - | - | - |
Net Interest Income | -700.00K (+1.45%) | -690.00K (+1.47%) | -680.00K (-12.82%) | -780.00K (-18.75%) | -960.00K (+1.05%) | -950.00K (-1.04%) | -960.00K (+12.94%) | -850.00K (-13.27%) | -980.00K (+1.03%) | -970.00K (+1.04%) | -960.00K (-1.03%) | -970.00K (+385.00%) | -200.00K | - | - | - | - | - | - | - | - |
Other Non Operating Income | 1.34M (-21.18%) | 1.70M (-19.81%) | 2.12M (-71.04%) | 7.32M (+167.15%) | 2.74M (+11.84%) | 2.45M (+99.19%) | 1.23M (-70.99%) | 4.24M (+142.29%) | 1.75M (+212.50%) | 560K (+211.11%) | 180K (-57.14%) | 420K (+27.27%) | 330K (+120.00%) | 150K (+1400.00%) | 10K (-50.00%) | 20K | - | - | - | - | - |
Net Income | |||||||||||||||||||||
Net Income From Continuing Operations | -35.71M (-3.36%) | -36.95M (+8.26%) | -34.13M (-4.69%) | -35.81M (+19.81%) | -29.89M (-5.59%) | -31.66M (+5.04%) | -30.14M (+53.70%) | -19.61M (-14.74%) | -23.00M (-4.33%) | -24.04M (+6.56%) | -22.56M (+20.51%) | -18.72M (+15.27%) | -16.24M (+7.55%) | -15.10M (-6.56%) | -16.16M (+13.80%) | -14.20M (-10.35%) | -15.84M (+48.45%) | -10.67M (+34.89%) | -7.91M (+10.32%) | -7.17M (+27.81%) | -5.61M |
Net Income | -35.71M (-3.36%) | -36.95M (+8.26%) | -34.13M (-4.69%) | -35.81M (+19.81%) | -29.89M (-5.59%) | -31.66M (+5.04%) | -30.14M (+53.70%) | -19.61M (-14.74%) | -23.00M (-4.33%) | -24.04M (+6.56%) | -22.56M (+20.51%) | -18.72M (+15.27%) | -16.24M (+7.55%) | -15.10M (-6.56%) | -16.16M (+13.80%) | -14.20M (-10.35%) | -15.84M (+48.45%) | -10.67M (+34.89%) | -7.91M (+10.32%) | -7.17M (+27.81%) | -5.61M |
Comprehensive Income Net Of Tax | -35.70M (-3.38%) | -36.95M (+8.10%) | -34.18M (-73.18%) | -127.45M (+326.40%) | -29.89M (-5.59%) | -31.66M (+5.04%) | -30.14M (-66.22%) | -89.22M | - | - | - | - | - | - | - | - | - | - | - | - | - |